Laurus Labs Reports 30% Revenue Growth in 9M FY26; EBITDA at ₹ 1,303 Cr, 26.1% Margins

Laurus Labs Ltd, a leading research and development driven pharmaceutical and biotech company in India, has announced its Q3 & 9M FY26 results. The company reported a revenue of ₹ 5,001 Cr, a 30% year-over-year growth. The EBITDA stood at ₹ 1,303 Cr, a 104% year-over-year growth, with margins at 26.1%. The company's CDMO division reported a 50% year-over-year growth, while the Bio business reported a 9% decrease due to customer-specific scale-up and scheduling issues. The Generics business reported a 26% increase, driven by higher ARV volumes and strong off-take in select molecules within developed markets. The company has also invested in capacity expansion and is advancing on commercial peptides manufacturing capability. The company has completed 109 quality audits in 9M and achieved a 2025 S&P Global Corporate Sustainability Assessment (CSA) & ESG score of 81 out of 100 points.